Novozymes Delta Ltd
Novozymes Delta Ltd develops and manufactures recombinant protein products using highly engineered, proprietary Saccharomyces cerevisiae yeast strains. The Company also undertakes flexible licensing of its yeast based expression system to offer its pharmaceutical, healthcare and biotech partners customised solutions to their recombinant protein needs.
Novozymes Delta’s capabilities range from state of the art molecular biology manipulation of yeast, through process development and analytics to commercial-scale manufacture of recombinant albumin in a Health Canada and FDA-inspected, cGMP-compliant facility.
The Company’s proprietary yeast based expression technologies and accompanying Intellectual Property portfolio has resulted in animal component free, high-yielding systems for the production of recombinant proteins at an extremely competitive cost of goods. Novozymes Delta’s protein expression abilities include both the production of native or modified polypeptides and the secretion of proteins genetically fused to albumin using albufuse™, the Company’s proprietary albumin fusion technology. Fusing proteins to albumin significantly enhances circulatory half-life.
Novozymes Delta Ltd develops and manufactures recombinant protein products using highly engineered, proprietary Saccharomyces cerevisiae yeast strains. The Company also undertakes flexible licensing of its yeast based expression system to offer its pharmaceutical, healthcare and biotech partners customised solutions to their recombinant protein needs.
Novozymes Delta’s capabilities range from state of the art molecular biology manipulation of yeast, through process development and analytics to commercial-scale manufacture of recombinant albumin in a Health Canada and FDA-inspected, cGMP-compliant facility.
The Company’s proprietary yeast based expression technologies and accompanying Intellectual Property portfolio has resulted in animal component free, high-yielding systems for the production of recombinant proteins at an extremely competitive cost of goods. Novozymes Delta’s protein expression abilities include both the production of native or modified polypeptides and the secretion of proteins genetically fused to albumin using albufuse™, the Company’s proprietary albumin fusion technology. Fusing proteins to albumin significantly enhances circulatory half-life.